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Abstract
Background: In Tanzania, little is known on the species distribution and antifungal susceptibility
profiles of yeast isolates from HIV-infected patients with primary and recurrent oropharyngeal
candidiasis.
Methods: A total of 296 clinical oral yeasts were isolated from 292 HIV-infected patients with
oropharyngeal candidiasis at the Muhimbili National Hospital, Dar es Salaam, Tanzania.
Identification of the yeasts was performed using standard phenotypic methods. Antifungal
susceptibility to fluconazole, itraconazole, miconazole, clotrimazole, amphotericin B and nystatin
was assessed using a broth microdilution format according to the guidelines of the Clinical and
Laboratory Standard Institute (CLSI; M27-A2).
Results: Candida albicans was the most frequently isolated species from 250 (84.5%) patients
followed by C. glabrata from 20 (6.8%) patients, and C. krusei from 10 (3.4%) patients. There was no
observed significant difference in species distribution between patients with primary and recurrent
oropharyngeal candidiasis, but isolates cultured from patients previously treated were significantly
less susceptible to the azole compounds compared to those cultured from antifungal naïve patients.
Conclusion: C. albicans was the most frequently isolated species from patients with oropharyngeal
candidiasis. Oral yeast isolates from Tanzania had high level susceptibility to the antifungal agents
tested. Recurrent oropharyngeal candidiasis and previous antifungal therapy significantly correlated
with reduced susceptibility to azoles antifungal agents.
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Background
Oropharyngeal candidiasis (OPC) is the most frequent
opportunistic infection encountered in human immuno-
deficiency virus (HIV)-infected individuals [1-4]. It occurs
in up to 90% at some point during the course of HIV dis-
ease [1,3,4]. The occurrence of OPC is associated with
CD4 T-lymphocyte below 200 cells/mm3, high viral loads
and disease progression [2,5,6]. The prolonged course of
HIV infection predisposes these patients to recurrent epi-
sodes of OPC that can increase in frequency and severity
with progressive HIV disease [7]. The advent of highly
active antiretroviral therapy (HAART) has permitted sup-
pression of viral replication and a partial recovery of CD4
T-lymphocyte count in HIV infected patients [8].
Although the incidence and prevalence of opportunistic
infections have been reduced worldwide due to use of
HAART [9-12], OPC remains the most frequent HIV-asso-
ciated oral lesion in most developing countries, including
Tanzania [6].
The prolonged management of OPC might cause the
development of drug-resistant OPC and there have been
reports of emergence of resistance to antifungal agents in
HIV/AIDS patients with OPC [13,14]. OPC due to resist-
ant Candida isolates fails to respond to antifungal treat-
ment with appropriate doses for a standard duration of
time [15,16]. The other possibility is that, repeated expo-
sure to antifungal agents may predispose to a shift to non-
albicans  Candida  species and associated refractory and
recurrent infections [17-20]. However, a surveillance
study done in the United Kingdom demonstrated that
there was little difference in antifungal susceptibilities of
Candida  species isolated from immunocompetent
patients who had a history of previous antifungal therapy
compared with those who had not received antifungal
treatment [21].
OPC increases morbidity and mortality and reduces
length and quality of life of HIV/AIDS patients, and there-
fore requires prompt diagnosis and adequate therapy. In
vitro susceptibility testing is clinically useful in predicting
which patients are likely to respond to therapy [22]. In
Tanzania, like many other developing countries, in vitro
antifungal testing is not performed routinely [23,24].
Therefore, little is known regarding the in vitro antifungal
susceptibility of Candida  species isolated from HIV-
infected patients with OPC in Tanzania.
The aim of our study was to determine the species distri-
bution of Candida isolates obtained from Tanzanian HIV-
infected patients with primary and recurrent OPC. For
each isolate the susceptibility profiles of six antifungal
agents was determined and compared for treatment naive
patients and repeatedly antifungal exposed patients.
Methods
Patients and setting
Participants were recruited at the Muhimbili National
Hospital (MNH) HIV clinic in Dar es Salaam, Tanzania
from January 2006 to September 2007. Patients were eli-
gible for the study if they were HIV-positive, 18 years of
age and above with clinical picture of OPC, characterized
by creamy, white, curd like patches, or by typical ery-
thematous lesions on the oral or/and pharyngeal mucosa.
Patients were included after obtaining their written
informed consent. Patients were interviewed using a
standard structured questionnaire and their hospital
records were also used to determine the previous episodes
of OPC, use of antifungal agents and past medical condi-
tions. A standard oral examination method recom-
mended by WHO was used [25]. Blood was collected in
EDTA tubes from each patient for enumeration of CD4+
and CD8+ T cells using a fluorescent activated cell sorter
(FACS) count machine after staining patients' blood with
monoclonal antibodies [26]. Primary OPC was defined as
the one that occur for the first time and recurrent OPC as
the second episode and above during the course of HIV
disease.
Oral isolates and species identification
Specimens were obtained by firmly swabbing the lesion
site with sterile cotton wool swab [27]. The swabs were
cultured on sabouraud dextrose agar (SDA) (Oxoid Ltd,
Hampshire, England) supplemented with 0.02% chlo-
ramphenicol and incubated aerobically at 30°C for 5
days. Isolates were identified to species level by colonial
morphology on SDA and microscopic morphology. The
germ tube production test was done. To distinguish
between C. albicans and C. dubliniensis; all germ tube pos-
itive isolates were subcultured on SDA and incubated at
45°C aerobically and an isolate which did not grow at
45°C, was identified using AUXACOLOR 2 (Bio-Rad,
France). Germ tube negative yeasts were identified using
AUXACOLOR 2 (Bio-Rad, France) and the auxanographic
method [28]. In the presence of multiple colony mor-
phologies, all were identified to species level. After the
final identification, isolates were stored at -80°C in 50%
glycerol until susceptibility tests were performed.
In vitro antifungal susceptibility testing
The in vitro activities of fluconazole (Pfizer, Kent, UK),
itraconazole, miconazole (Janssen-Pharmaceutica N.V.,
Beerse, Belgium), clotrimazole (Sigma Aldrich, Stein-
heim, Germany), amphotericin B (Bristol-Myers Squibb,
Woerden, The Netherlands) and nystatin (Sigma Aldrich,
Steinheim, Germany) were assessed. The minimum inhib-
itory concentration (MIC) was determined using a broth
microdilution format (M27-A2) according to the guide-
lines of the Clinical and Laboratory Standard Institute
(CLSI) [29], and all the testing done in duplicates. TheBMC Microbiology 2008, 8:135 http://www.biomedcentral.com/1471-2180/8/135
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respective manufacturers provided the antifungal agents
as standard powders. Fluconazole was dissolved in sterile
distilled water and itraconazole, miconazole, clotrima-
zole, amphotericin B and nystatin were dissolved in dime-
thyl sulfoxide (DMSO) to make stock solutions. RPMI
1640 medium with L-glutamine, without sodium bicar-
bonate (GIBCO BRL, Life Technologies, Woerden, The
Netherlands) and buffered with morpholinepropanesul-
fonic acid (MOPS) at 0.165 M (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) was used as a test medium.
Serial twofold dilutions and final dilutions of each anti-
fungal agent were prepared in RPMI 1640 medium [29].
The range of fluconazole concentrations tested was
0.063–64 μg/ml and for itraconazole, miconazole, clot-
rimazole, amphotericin B and nystatin the range was
0.016–16 μg/ml. Aliquots of 100 μl of each antifungal
agent at a concentration two times the targeted final con-
centration were dispensed in the wells of flat bottom 96-
well microtiter plates (Costar, Corning, N.Y). Prior to test-
ing, isolates were subcultured on SDA at 30°C under aer-
obic conditions for 24 hours. Yeast inocula were prepared
spectrophotometrically and further diluted in RPMI 1640
medium in order to obtain a final concentration of 0.5 to
2.5 × 103 CFU/ml [29]. A constant volume (100 μl) of the
innoculum was added to each microdilution well contain-
ing 100 μl of the serial dilution of the antifungal agents to
reach final concentrations. The microtiter plates were
incubated at 35°C for 48 hours.
The minimum inhibitory concentrations (MICs) were
determined after 48 hours, after which readings were per-
formed spectrophotometrically with a microplate reader
(Anthos ht III; Anthos Labtec Instruments, Salzburg, Aus-
tria) at 405 nm using modified broth microdilution for-
mat (M27-A2) as described previously [21,30]. The
optical densities (ODs) of the blanks were subtracted
from the ODs of the inoculated plates and the percentages
of growth for each well were calculated. The MICs of pol-
yene antifungals (amphotericin B and nystatin) were
defined as the lowest concentrations that inhibit growth
by 100%. The MICs of the azoles (fluconazole, itracona-
zole, clotrimazole and miconazole) were defined as the
lowest concentrations that inhibit growth by 50%. Anti-
fungal activity was expressed as the MIC of each isolate to
the antifungal agent. The MIC values were the average of
MICs of the first and duplicate measurement. The MIC
values for fluconazole and itraconazole were compared to
the CLSI interpretative guidelines on antifungal suscepti-
bility testing. MICs of ≤ 8 μg/ml considered as susceptible,
16 – 32 μg/ml as susceptible dose dependent (SSD) and ≥
64 μg/ml as resistant for fluconazole and for itraconazole,
≤ 0.125 μg/ml as susceptible, 0.25 – 0.5 μg/ml as SDD and
≥ 1 μg/ml as resistant [29]. American Type Culture Collec-
tion (ATCC) strains recommended by CLSI, C. parapsilosis
(ATCC 22019) and C. krusei (ATCC 6258) were used as
controls for each test.
Ethical issues
The Ethics Committees of the Muhimbili University of
Health and Allied Sciences (MUHAS) and the Muhimbili
National Hospital, Dar es salaam, Tanzania approved the
study. All patient information and test results were confi-
dentially kept.
Data and statistical analysis
The geometric mean of MICs, MIC50 and MIC90 were cal-
culated. The MIC50 and MIC90 values were calculated as
the concentrations of antifungals that were able to inhibit
50% and 90% of the isolates, respectively. The high and
low off-scale MICs were included in the analysis by con-
version to the next higher and lower drug concentrations,
respectively. An isolate was considered resistant to fluco-
nazole and itraconazole if average MICs were greater or
equal to their respective CLSI breakpoints [29]. Data were
analyzed using the SPSS version 14.0. Antifungal suscep-
tibility of isolates from patients with primary OPC was
compared with those of isolates from patients with recur-
rent OPC. Similarly, the antifungal susceptibility of iso-
lates from patients who had not received an antifungal
agent was compared with those of isolates from patients
who had previously received antifungal therapy. Compar-
ison of species distribution and antifungal susceptibility
rates was performed using Fisher's exact test and Mann-
Whitney U-test. A P-value of < 0.05 was considered signif-
icant.
Results
Patients' characteristics
Two hundred and ninety two (292) HIV infected patients
with OPC, 164 with primary OPC and 128 with recurrent
OPC, participated in the study. Pseudomembranous can-
didiasis was the most predominant type of OPC 194
(66.4%) followed by combinations of pseudomembra-
nous and erythematous 66 (22.6%), pseudomembranous
and angular cheilitis 12 (4.1%), pseudomembranous and
hyperplastic candidiasis 9 (3.1%), hyperplastic candidia-
sis 7 (2.4%) and erythematous candidiasis were the least
4 (1.4%). Patients' ages ranged from 18 to 75 years,
median 34 years of whom 218 (74.7%) were females and
74 (25.3%) were males. The majority of the patients with
recurrent OPC had a history of one previous episode of
OPC (n = 92, 71.8%) and the range of recurrences was 1
to 4 episodes. Their CD4+ T cells values ranged from 1 to
699 cells/mm3 with a median count of 93 cells/mm3 and
229 patients (78.4%) had CD4+ T cells count below 200
cells/mm3. One hundred and seven patients (36.6%) were
under HAART, predominantly (72.9%) a combination of
stavudine, lamivudine and nevirapine and 65 patients
(60.7%) were on HAART for duration below six months.BMC Microbiology 2008, 8:135 http://www.biomedcentral.com/1471-2180/8/135
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Distribution of isolates
Two hundred and ninety six (296) clinical oral yeasts were
isolated from the 292 patients with OPC. One hundred
and sixty five (165) isolates were from patients with pri-
mary OPC and 131 isolates from patients with recurrent
OPC. The species distribution as presented in Table 1
show that C. albicans was the most frequently isolated spe-
cies (84.5%) followed by C. glabrata (6.8%) and C. krusei
(3.4%).  Saccharomyces cerevisiae was the only isolated
non-Candida  species from these patients. Four patients
had mixed infection, two harbored C. albicans and C. kru-
sei and two other patients had C. glabrata and C. krusei.
Among four patients with mixed infection, three patients
had recurrent OPC and one patient who harbored C. gla-
brata and C. krusei had primary OPC. There was no statis-
tically significant difference in species distribution
between patients with primary and recurrent OPC (P =
0.264).
In vitro susceptibility of isolates
The results of antifungal susceptibility, as summarized in
Table 2, show that only fifteen of the 296 isolates (5%)
were resistant to fluconazole, while 20 (6.8%) isolates
were susceptible dose dependent (SDD) and 261 (88.2%)
of all tested isolates were susceptible to fluconazole.
Twenty-five (8.4%) isolates were resistant to itraconazole,
while 26 (8.8%) were SDD and 245 (82.8%) isolates were
susceptible to itraconazole. Fluconazole exhibited greatest
activity against C. albicans with no resistant strain found;
overall five C. albicans isolates (2%) were SDD, while 245
(98%) were susceptible to this agent. All C. krusei isolates
were resistant to fluconazole while 4 of the 8 (50%) C.
tropicalis isolates were resistant to fluconazole. Only one
of the isolated C. glabrata isolates (5%) was resistant to
fluconazole, while six (30%) were fully susceptible and 13
(65%) were SDD. Moreover, all isolated C. kefyr, S. cerevi-
siae and C. dubliniensis isolates were fully susceptible to
fluconazole, and the only isolated C. pintolopesii was SDD.
Ten (4%) of the isolated C. albicans were resistant to itra-
conazole, while seven (2.8%) isolates were SDD and 233
(93.2%) isolates were susceptible to this antifungal agent.
None of the C. glabrata isolated was fully susceptible to
itraconazole, but 9 (45%) were SDD and 11 (55%) resist-
ant. None of C. krusei isolates was resistant to itracona-
zole, while 5 (50%) isolates were SDD. C. pintolopesii was
resistant while C. dubliniensis was fully susceptible to itra-
conazole. All the three S. cerevisiae isolates were SDD to
itraconazole.
Correlation between MIC and recurrence of OPC
In this study, among 292 patients investigated 173
patients (59.2%) had a prior history of antifungal usage,
while 119 patients (40.8%) were antifungal treatment
naïve. Therefore, 176 isolates (59.5%) were isolated from
patients who had previous exposure to antifungal therapy
(Table 3). Among patients exposed to antifungal therapy,
94 (54.3%) were exposed once, 47 (27.2%) twice and 32
(18.5%) were exposed three times and above. All patients
with recurrent OPC had exposure to antifungal agents
before enrollment in our study. Regarding patients with
primary OPC, 45 (27.4%) were exposed to antifungal
agents due to other fungal infections including vaginal
candidiasis, skin fungal infections and cryptococcal men-
ingitis. Most of patients had exposure to more than one
antifungal agent, including fluconazole, clotrimazole,
nystatin, miconazole and ketoconazole. Among exposed
patients, 149 patients (86.1%) were exposed to azole
compounds with fluconazole being the predominant
(49.7%).
There were significant differences in the MIC distributions
for isolates from patients with primary and recurrent OPC
for amphotericin B (P = 0.041), itraconazole (P = 0.008),
miconazole (P = 0.045), and clotrimazole (P = 0.013). No
significant difference in MIC distribution between isolates
was observed for nystatin (P = 0.608) and fluconazole (P
= 0.133). Based on CLSI interpretative breakpoints, fluco-
nazole resistance for species isolated from patients with
Table 1: Distribution of oral yeast isolates among HIV-infected patients with primary and recurrent oropharyngeal candidiasis
Species Patients with primary OPC Patients with recurrent OPC All patients with primary and recurrent 
OPC
n (%) n (%) n (%)
Candida albicans 141 (47.6) 109 (36.9) 250 (84.5)
Candida glabrata 8 (2.7) 12 (4.1) 20 (6.8)
Candida krusei 4 (1.35) 6 (2.05) 10 (3.4)
Candida tropicalis 6 (2.02) 2 (0.68) 8 (2.7)
Candida kefyr 3( 1 ) - - 3 ( 1 )
Saccharomyces cerevisiae 2 (0.68) 1 (0.3) 3 (1)
Candida pintolopesii - - 1 (0.3) 1 (0.3)
Candida dubliniensis 1 (0.3) - - 1 (0.3)
Total of all isolates 165 (55.7) 131 (44.3) 296 (100)BMC Microbiology 2008, 8:135 http://www.biomedcentral.com/1471-2180/8/135
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Table 2: In vitro antifungal susceptibility of all oral yeast isolates (n = 296)
Species/Antifungal agent MIC (μ/ml) %R*
MIC Range MIC50 MIC90 GM
C. albicans (250)
Amphotericin B 0.125 – 1 0.5 0.5 0.326
Nystatin 2 – >16 4 4 3.377
Fluconazole 0.063 – 32 0.25 2 0.330 0
Itraconazole 0.016 – >16 0.016 0.063 0.021 4
Miconazole 0.016 – 4 0.016 0.063 0.025
Clotrimazole 0.125 – 2 1 2 0.474
C. glabrata (20)
Amphotericin B 0.5 – 1 0.5 1 0.545
Nystatin 2 – 4 4 4 3.668
Fluconazole 2 – 64 16 32 13.22 5
Itraconazole 0.016 – 4 1 4 0.615 55
Miconazole 0.063 – 0.5 0.25 0.5 0.189
Clotrimazole 0.125 – 2 1 2 0.474
C. krusei (10)
Amphotericin B 0.5 – 1 1 1 0.683
Nystatin 2 – 8 4 4 0.965
Fluconazole 64 – >64 64 >64 76.1 100
Itraconazole 0.031 – 0.5 0.125 0.5 0.134 0
Miconazole 1 – 2 2 2 1.464
Clotrimazole 0.063 – 0.25 0.125 0.125 0.116
C. tropicalis (8)
Amphotericin B 0.25 – 1 0.5 - 0.458
Nystatin 2 – 4 4 - 3.084
Fluconazole 1 – >64 16 - 14.67 50
Itraconazole 0.016 – 2 0.5 - 0.176 37.5
Miconazole 0.125 – 4 2 - 0.840
Clotrimazole 0.031 – 4 2 - 0.337
C. kefyr (3)
Amphotericin B 0.5 – 0.5 0.5 - 0.5
Nystatin 2 – 4 2 - 2.244
Fluconazole 0.25 – 0.5 0.5 - 0.396 0
Itraconazole 0.016 – 0.031 0.031 - 0.019 0
Miconazole 0.016 – 0.016 0.016 - 0.016
Clotrimazole 0.016 – 0.016 0.016 - 0.016
C. pintolopesii (1)
Amphotericin B 0.5 - - -
N y s t a t i n 4 ---
Fluconazole 16 - - - 0
Itraconazole 1 - - - 100
Miconazole 0.25 - - - -
Clotrimazole 1 - - - -
C. dubliniensis (1)
Amphotericin B 0.25 - - -
N y s t a t i n 4 ---
Fluconazole 0.5 - - - 0
Itraconazole 0.016 - - - 0
Miconazole 0.016 - - -
Clotrimazole 0.016 - - -
S. cerevisiae (3)
Amphotericin B 0.5 – 1 0.5 - 0.445BMC Microbiology 2008, 8:135 http://www.biomedcentral.com/1471-2180/8/135
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primary OPC and recurrent OPC was noted in 9 isolates
(5.5%) and 6 isolates (4.6%), respectively, which was not
different (P = 0.581). However for itraconazole, more iso-
lates cultured from patients with recurrent OPC exhibited
reduced susceptibility compared with those cultured from
patients with primary OPC (P = 0.03).
However, when the correlation between in vitro suscepti-
bility and previous exposure to antifungal agents was
determined, it was found that all azole compounds tested
were less active against Candida  isolates cultured from
patients who had been previously exposed to any antifun-
gal drug compared with those cultured from the treatment
naïve group (fluconazole, P  = 0.037; itraconazole, P =
0.002; miconazole, P = 0.015; clotrimazole, P = 0.007).
No significant differences in MICs of amphotericin B and
nystatin between the two groups of isolates were noted (P
= 0.087 and P = 0.117), respectively.
In the present study, two of the five C. albicans isolates that
were SDD to fluconazole were also SDD to itraconazole
and three isolates were resistant to itraconazole. Itracona-
zole resistance was in 25 (8.4%) of all tested isolates,
among which 17 isolates (68%) had MICs of ≥ 1 μg/ml for
clotrimazole.
Discussion
The present study demonstrates that in Tanzania primary
and recurrent OPC is predominantly caused by C. albicans.
There was no significant difference in species distribution
between the two groups of patients (P = 0.264). There are
only a limited number of studies done in African coun-
tries regarding distribution of oral yeasts in HIV-infected
patients. However, similar to our results, studies done in
South Africa demonstrated that more than 80% of oral
yeast isolates from HIV-infected patients were of the spe-
cies C. albicans [23,31,32] that is not different to reports
from other continents [19,33,34]. On looking at distribu-
tion of isolates from patients with recurrent OPC and pre-
viously exposed to antifungal therapy, the current results
are contrary to what was expected. Previously studies sug-
gested that, repeated exposure to antifungal agents and
recurrent infections might predispose to a shift to non-
albicans Candida species [19,20]. This was not the case in
this study, which could be explained by the fact that,
majority of the patients with recurrent OPC had only one
previous episode of OPC and among patients previously
exposed to antifungal therapy almost a half were exposed
only once. Interestingly, the first C. dubliniensis has been
isolated from a Tanzanian HIV/AIDS patient with primary
OPC and without previous history of antifungal therapy.
Nystatin 2 – 4 4 - 2.828
Fluconazole 8 – 8 8 - 8 0
Itraconazole 0.25 – 0.5 0.25 - 0.353 0
Miconazole 0.063 – 0.25 0.063 - 0.088
Clotrimazole 0.063 – 1 0.063 - 0.099
All isolates (296)
Amphotericin B 0.125 – 1 0.5 0.5 0.352
Nystatin 2 – >16 4 4 3.39
Fluconazole 0.063 – >64 0.5 16 0.592 5
Itraconazole 0.016 – >16 0.016 0.5 0.031 8.4
Miconazole 0.016 – 4 0.031 1 0.036
Clotrimazole 0.016 – 4 0.016 1 0.029
MIC50 – MIC value able to inhibit 50% of the isolates tested.
MIC90 – MIC value able to inhibit 90% of the sample tested.
GM – Geometric Mean.
R* – Percent resistance using interpretive breakpoint criteria of the CLSI (2002): Itraconazole resistance ≥ 1; Fluconazole resistance ≥ 64 μg/ml.
Table 2: In vitro antifungal susceptibility of all oral yeast isolates (n = 296) (Continued)
Table 3: In vitro susceptibility of oral isolates to fluconazole and itraconazole as related to previous antifungal therapy
Antifungal Previous antifungal (n = 176a) No previous antifungal (n = 128b) P-value
SS D D R S S D D R
Fluconazole 149 (84.7) 17 (9.7) 10 (5.7) 112 (93.3) 3 (2.5) 5 (4.2) 0.037
Itraconazole 133 (75.6) 22 (12.5) 21 (11.9) 112 (93.3) 4 (3.3) 4 (3.3) 0.002
Data are expressed as number of isolates (percentage).
S – Susceptible, SDD – Susceptible dose dependent, R – resistant.
Interpretive breakpoint criteria of the CLSI (2002): Fluconazole; S (MIC ≤ 8 μg/ml), SDD (MIC 16 – 32 μg/ml), R (MIC 64 μg/ml) and Itraconazole; 
S (MIC ≤ 0.125 μg/ml), SDD (MIC 0.25 – 0.5 μg/ml), R (MIC ≥ 1).
aC. albicans (143), C. glabrata (19), C. tropicalis (4), S. cerevisiae (2), C. pintolopesii (1).
bC. albicans (107), C. glabrata (1), C. tropicalis (4), C. kefyr (3), S. cerevisiae (1), C. dubliniensis (1).BMC Microbiology 2008, 8:135 http://www.biomedcentral.com/1471-2180/8/135
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Previous studies, reported that C. dubliniensis was prima-
rily isolated from patients with previous antifungal ther-
apy and/or recurrent OPC [35-37].
In the present study, there appears to be a significant rapid
induction of reduced susceptibility to azoles among oral
yeasts isolated from patients with recurrent OPC and a
previous history of antifungal therapy. This suggests that
patients with more recurrent episodes of OPC and repeat-
edly exposed to antifungal therapies pose a great risk of
reduced susceptibility to azole antifungal agents. Simi-
larly, previous studies reported that prolonged exposure
to antifungal therapy of these patients lead to reduced sus-
ceptibility of Candida  species [17,19,38,39]. Candida
resistance to azole compounds has frequently been attrib-
uted to a selective pressure caused by antifungal agents
and azole cumulative doses due to exposure to several
courses of short- or long-term suppressive therapies in
patients with OPC [38-40]. Similarly, the risk of develop-
ing OPC with reduced susceptibility to azoles has been
associated with greater duration of HIV infection and
severe immunosuppression [20].
Generally, even with the observed reduced susceptibility
to azoles among oral yeast isolated from patients with
recurrent OPC and previous history of antifungal therapy,
in the present study resistance to antifungal agents among
the tested isolates is relatively low. Resistance was mainly
among non-albicans Candida species that are primarily or
intrinsically resistant to azoles [19]. Fluconazole resist-
ance among all the tested isolates was 5%, which is similar
to that reported by other previous studies [21,41]. The rea-
son for the low fluconazole resistance could be explained
by the fact that, fluconazole was non affordable to most
HIV patients until October 2004, when the government
started to provide it for free to needy HIV-infected patients
as standard of care. In general, antifungal drug prophy-
laxis is rarely practiced in Tanzania. In the present study,
overall resistance of all tested isolates to itraconazole is
8.4%; slightly higher than that of fluconazole (5%). How-
ever, none of the investigated patients were exposed to
this antifungal agent before, indicating possible cross-
resistance following exposure to other compounds from
this class [42,43]. A relation between azole resistance and
previous azole exposure was found in this study, with
patients who were previously exposed to antifungal ther-
apy having isolates significantly more resistant to itraco-
nazole and fluconazole than those from treatment naïve
patients (P = 0.002) and (P = 0.037), respectively.
There are no interpretative breakpoint criteria for nystatin,
amphotericin B, miconazole and clotrimazole. However,
the results of the present study have shown that MICs of
miconazole, clotrimazole and amphotericin B was con-
centrated in a narrow range. Previous studies have shown
low MICs of miconazole and amphotericin B against
tested strains [17,21,24], which is in accordance with our
findings. The Tanzanian guidelines for management of
HIV and AIDS include fluconazole orally, miconazole,
nystatin oral suspension, 2% Sodium benzoate solution
or gentian violet solution and ketoconazole for oropha-
ryngeal and esophageal candidiasis [44]. Amphotericin B
is used in topical forms as an oral suspension, but the drug
is not available for this indication in Tanzania The present
study would support the effectiveness of amphotericin B,
miconazole, clotrimazole, itraconazole and fluconazole
for treatment of OPC in HIV/AIDS patients. However,
continuously surveillance programs are needed in order
to identify possible changes in the species distribution,
antifungal susceptibility patterns of oral yeasts and in vivo
efficacy of these antifungal agents.
Conclusion
This study demonstrates that C. albicans is the most fre-
quently isolated species from both patients with primary
and recurrent OPC. Oral yeast isolates from Tanzania
have high level susceptibility to fluconazole, itraconazole,
miconazole, clotrimazole and amphotericin B. Recurrent
oropharyngeal candidiasis and previous antifungal ther-
apy significantly correlated with reduced susceptibility to
fluconazole, itraconazole, miconazole, and clotrimazole.
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